

NUVAXOVID: POWERFUL AGAINST COVID-19, GENTLE ON PATIENTS.¹

The non-mRNA COVID-19 Vaccine With Manageable Side Effects.^{1*}

NUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years and older.

NUVAXOVID is also indicated for individuals 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19.

NUVAXOVID is the ONLY non-mRNA, protein-based COVID-19 vaccine^{1,2}



Protein-based

NUVAXOVID directly provides the protein needed for antibody production^{1,2}



Recombinant

Developed using technology already present in modern flu vaccines^{1,3}



Adjuvanted

The potent adjuvant provides a robust and enhanced immune response^{1,4}

What makes **NUVAXOVID** different from mRNA COVID-19 vaccines?

How **NUVAXOVID** Builds Immunity²:

STEP 1

Spike proteins contained in the vaccine are recognized by the immune system

STEP 2

Immune system produces antibodies and activates other immune cells

How **mRNA Vaccines** Build Immunity²:

STEP 1

mRNA uses cells' machinery to make the spike protein

STEP 2

Cells display spike protein antigens on their surface, where it is recognized by the immune system

STEP 3

Immune system produces antibodies and activates other immune cells

Who can receive **NUVAXOVID**?

Patients aged 65+ AND patients aged 12-64 who have ≥1 underlying condition that puts them at high risk for severe outcomes from COVID-19. NUVAXOVID can be used as a primary series OR seasonal dose following vaccination with any approved COVID-19 vaccine.¹

*In the pivotal clinical trial, most common side effects were mild-to-moderate and ≤0.1% of patients experienced Grade 4 solicited adverse reactions.¹

**CPT Code
91304**

Use this CPT code when administering NUVAXOVID to ensure you receive proper payment. This CPT code is unique to NUVAXOVID – the ONLY non-mRNA COVID-19 vaccine.^{1,2}

IMPORTANT SAFETY INFORMATION

Do not administer NUVAXOVID to individuals with a known history of severe allergic reaction (eg, anaphylaxis) to any component of NUVAXOVID or to individuals who had a severe allergic reaction (eg, anaphylaxis) following a previous dose of a NUVAXOVID

Please see additional Important Safety Information on back page.
Please see the full Prescribing Information [here](#).



COULD OFFERING YOUR PATIENTS A non-mRNA COVID-19 VACCINE MAKE THE DIFFERENCE?

NUVAXOVID OFFERS POWERFUL PROTECTION AGAINST COVID-19^{1,5}

~90%

Efficacy preventing COVID-19 in the pivotal trial

Primary endpoint: efficacy in preventing PCR-confirmed symptomatic mild, moderate, or severe COVID-19 from 7 days after the second dose.

(95% CI: 82.5, 93.8; $p < 0.001$) N=25,510

ZERO NUVAXOVID PATIENTS HAD MODERATE-TO-SEVERE COVID-19 ILLNESS^{1,5}

100%

Protection from moderate-to-severe COVID-19[†]

Secondary endpoint: efficacy in preventing moderate-to-severe disease from then-circulating strains of virus.

(95% CI: 87.0, 100.0) N=25,452

The NUVAXOVID vaccine may not protect all participants.

Pivotal Trial Study Design: Phase 3, multicenter, randomized, observer-blinded, placebo-controlled clinical trial evaluating efficacy and safety in 29,943 adults aged 18 and older. Participants were stratified by age (18 to 64 years and ≥ 65 years) and assigned in a 2:1 ratio to receive NUVAXOVID or placebo. Data based on strains circulating at time of study^{1,5}

[†]Moderate disease was defined as high fever and objective evidence of lower respiratory tract infection. Severe COVID-19 was defined as the presence of clinically significant tachypnea, tachycardia, or hypoxia; receipt of intensive respiratory support; major dysfunction of one or more organ systems; admission to an intensive care unit; or death.⁵

NUVAXOVID had low reactogenicity and minimal disruptive side effects¹

In the pivotal clinical trial, the majority of adverse events were Grade 1 or 2 and did not prevent daily activities. Higher severity reactions (Grade 4) were experienced by $\leq 0.1\%$ of patients for each of the most frequent solicited adverse reactions.¹



Discover more about the efficacy and tolerability of NUVAXOVID

INDICATION

NUVAXOVID is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in adults 65 years and older

NUVAXOVID is also indicated for individuals 12 through 64 years who have at least one underlying condition that puts them at high risk for severe outcomes from COVID-19

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION

Do not administer NUVAXOVID to individuals with a known history of severe allergic reaction (eg, anaphylaxis) to any component of NUVAXOVID or to individuals who had a severe allergic reaction (eg, anaphylaxis) following a previous dose of a NUVAXOVID

MANAGEMENT OF ACUTE ALLERGIC REACTIONS

Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of NUVAXOVID

MYOCARDITIS and PERICARDITIS

Clinical trials data provide evidence for increased risks of myocarditis and pericarditis following administration of NUVAXOVID. There have been post-marketing reports of myocarditis and pericarditis following administration of NUVAXOVID and other authorized or approved COVID-19 vaccines

SYNCOPE

Syncope (fainting) may occur in association with administration of injectable vaccines, including NUVAXOVID. Procedures should be in place to avoid injury from fainting

ALTERED IMMUNOCOMPETENCE

Immunocompromised persons, including individuals receiving immunosuppressive therapy, may have a diminished immune response to NUVAXOVID

NUVAXOVID may not protect all vaccine recipients

COMMON ADVERSE REACTIONS

The most commonly reported ($>10\%$) solicited adverse reactions included: injection site pain/tenderness, fatigue/malaise, muscle pain, headache, joint pain, nausea/vomiting, injection site redness, injection site swelling, and fever

Please see the full Prescribing Information [here](#).

References: 1. Nuvaxovid. Prescribing Information. Novavax, Inc. 2. Centers for Disease Control and Prevention. Understanding how COVID-19 vaccines work. May 2023. Accessed July 14, 2023. <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/how-they-work.html> 3. Cid R, Bolivar J. Platforms for production of protein-based vaccines: from classical to next-generation strategies. *Biomolecules*. 2021;11(8):1072. doi: 10.3390/biom11081072 4. Bengtsson KL, Song H, Stertman L, et al. Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. *Vaccine*. 2016;34(16):1927-1935. doi:10.1016/j.vaccine.2016.02.033 5. Dunkle LM, Kotloff KL, Gay CL, et al; 2019nCoV-301 Study Group. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. *N Engl J Med*. 2022;386(6):531-543. doi: 10.1056/NEJMoa2116185

sanofi

MAT-US-2505042-v1.0-07/2025 © 2025 Sanofi

Sanofi 1 Discovery Drive, Swiftwater, Pennsylvania 18370 www.sanofi.us

 **Nuvaxovid**[®]
(COVID-19 Vaccine, Adjuvanted)